Effect of site-specific PEGylation on the fibrinolytic activity, immunogenicity, and pharmacokinetics of staphylokinase  

作　　者：Jianwei Liu Zhu Wang Jintian He Gaizhen Wang Rongbo Zhang Baohua Zhao 

机构地区：[1]College of Life Science, Hebei Normal University, Shijiazhuang 050024, China [2]College of Environmental Science and Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, China

出　　处：《Acta Biochimica et Biophysica Sinica》2014年第9期782-791,共10页生物化学与生物物理学报（英文版）

摘　　要：The bacterial plasminogen-activator staphylokinase （Sak） is a promising thrombolytic agent for treating acute myocar- dial infarction. To effectively reduce the immunogenicity of Sak while maintaining its fibrinolytic activity, site-specific PEGylation was performed in the present study. The che- moselective cysteine PEGylation site was selected within an immunodominant region （amino acid residues 71-87） using an in sUico approach. The PEGylated Sak variants pre- pared in this study showed a purity of 〉97.0%. PEGylation at Position 80 resulted in a Sak variant Sak（E80C-PEG） which has similar fibrinolytic activity and thermostability compared with the native recombinant staphylokinase （r-Sak）. The immunogenicity of Sak（E80C-PEG） in guinea pigs was greatly reduced compared with the native r-Sak. Furthermore, preliminary pharmacokinetic results sug- gested that the plasma clearance of Sak（E80C-PEG） from the blood stream of rabbit was significantly decreased com- pared with that of r-Sak, resulting in a 2.8-fold increase of initial half-life and a 3.8-fold increase of systemic availabil- ity. In summary, these results demonstrated that site-specif- ic PEGylation yielded a novel Sak variant Sak（E80C-PEG） with remarkable advantages over the unmodified Sak.The bacterial plasminogen-activator staphylokinase （Sak） is a promising thrombolytic agent for treating acute myocar- dial infarction. To effectively reduce the immunogenicity of Sak while maintaining its fibrinolytic activity, site-specific PEGylation was performed in the present study. The che- moselective cysteine PEGylation site was selected within an immunodominant region （amino acid residues 71-87） using an in sUico approach. The PEGylated Sak variants pre- pared in this study showed a purity of 〉97.0%. PEGylation at Position 80 resulted in a Sak variant Sak（E80C-PEG） which has similar fibrinolytic activity and thermostability compared with the native recombinant staphylokinase （r-Sak）. The immunogenicity of Sak（E80C-PEG） in guinea pigs was greatly reduced compared with the native r-Sak. Furthermore, preliminary pharmacokinetic results sug- gested that the plasma clearance of Sak（E80C-PEG） from the blood stream of rabbit was significantly decreased com- pared with that of r-Sak, resulting in a 2.8-fold increase of initial half-life and a 3.8-fold increase of systemic availabil- ity. In summary, these results demonstrated that site-specif- ic PEGylation yielded a novel Sak variant Sak（E80C-PEG） with remarkable advantages over the unmodified Sak.

关 键 词：STAPHYLOKINASE site-specific pEGylation IMMUNOGENICITY PHARMACOKINETIC fibrinolytic activity 

分 类 号：Q78[生物学—分子生物学] S562[农业科学—作物学]